DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

22 Drugs in Development

22 Drugs in Development

DIGITAL CONTENT

6 NEWS #PharmaBuzz

media
6 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

22DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ipi-549, 1693758-51-8, Eganelisib [usan], Pi3k-gamma inhibitor ipi-549, Fof5155fmz, Ipi549

Molecular Formula

C₃₀H₂₄N₈O₂

Molecular Weight

528.6 g/mol

InChI Key

XUMALORDVCFWKV-IBGZPJMESA-N

FDA UNII

FOF5155FMZ

Eganelisib is an orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.

1 2D Structure

Eganelisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

2.1.2 InChI

InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1

2.1.3 InChI Key

XUMALORDVCFWKV-IBGZPJMESA-N

2.1.4 Canonical SMILES

CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N

2.1.5 Isomeric SMILES

C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N

2.2 Other Identifiers

2.2.1 UNII

FOF5155FMZ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-amino-n-((1s)-1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide

2. Ipi-549

2.3.2 Depositor-Supplied Synonyms

1. Ipi-549

2. 1693758-51-8

3. Eganelisib [usan]

4. Pi3k-gamma Inhibitor Ipi-549

5. Fof5155fmz

6. Ipi549

7. Chembl3984425

8. 2-amino-n-[(1s)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

9. (s)-2-amino-n-(1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2- Dihydroisoquinolin-3-yl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide

10. 2-amino-n-[(1s)-1-{8-[(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

11. Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 2-amino-n-((1s)-1-(1,2-dihydro-8-(2-(1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-3-isoquinolinyl)ethyl)-

12. Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-n-[(1s)-1-[1,2-dihydro-8-[2-(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-

13. Eganelisib [inn]

14. Unii-fof5155fmz

15. Eganelisib [who-dd]

16. Gtpl9563

17. Schembl16629991

18. Dtxsid301336580

19. Ipi-549(ipi549)

20. Amy16733

21. Ex-a1057

22. V7y

23. Bdbm50192880

24. Mfcd30533720

25. Nsc795067

26. Nsc801002

27. S8330

28. Who 11571

29. Zinc584906867

30. Ccg-269905

31. Cs-6106

32. Nsc-795067

33. Nsc-801002

34. Compound 26 [pmid: 27660692]

35. Ac-29898

36. As-55938

37. Hy-100716

38. A16332

39. 2-amino-n-((1s)-1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide

40. 2-amino-n-[(1s)-1-{8-[2-(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl- 1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

2.4 Create Date

2015-10-12

3 Chemical and Physical Properties

Molecular Formula	C₃₀H₂₄N₈O₂
Molecular Weight	528.6 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Exact Mass	528.20222204 g/mol
Monoisotopic Mass	528.20222204 g/mol
Topological Polar Surface Area	123 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	1060
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1